Cary Pfeffer

Cary Pfeffer is the interim CEO of Jounce Therapeutics and partner of Third Rock Ventures. Dr. Pfeffer has more than 20 years of business development and transaction experience, facilitating the successful development and implementation of leading collaborations across the spectrum of newly emerging and established biotech companies. He joined Third Rock Ventures in 2007 and drives the firm's overall interface strategy with pharmaceutical and large biotech companies as well as academic institutions. Additionally, he supports the business development efforts within Third Rock's portfolio companies and is a board member of Eleven Biotherapeutics, Ablexis, Edimer and Taris Biomedical. Before joining Third Rock Ventures, Dr. Pfeffer founded The Pfeffer Group, which provided business development and strategy advisory services for leading biotechnology and life sciences companies. Prior to that, he spent more than 10 years at Biogen in a variety of executive domestic and international management roles focused on business and market development, product development and commercial operations. Earlier in his career, Dr. Pfeffer spent several years in corporate finance in the Health Care Investment Banking Group of Lehman Brothers. Dr. Pfeffer holds an M.D. from the University of Pennsylvania, an M.B.A. from the Wharton School and a B.A. in biochemistry from Columbia University.